Building a European reputation in pharmaceuticals and biotechnology

Pharmaceutical and biotechnology companies need a European reputation that supports informed decisions about science, access and long-term commitment. Public visibility can help explain a research program or an investment, but it cannot substitute for evidence or the relevant authorization. An American business should organize communication around the different decisions made by regulators, healthcare professionals, payers, patients and employees.

Separate regulatory approval from access in practice. The European Medicines Agency explains the centralized authorization route and its scope, including the role of the European Commission's decision. ^[1] A European authorization does not, on its own, determine the price, reimbursement conditions or practical availability of a medicine in every country. Commercial and communications teams need to use the correct status language and understand which national decisions remain before announcing what patients can access.

Health technology assessment adds another layer. The EU framework for joint clinical assessments began covering new cancer medicines and advanced therapy medicinal products from January 12, 2025. These assessments support national HTA processes through analysis of relative clinical effects. ^[2] They should not be described as a uniform European reimbursement decision. An American company needs an evidence strategy that addresses the relevant clinical comparisons while preparing for the questions that remain within national systems.

Build the corporate narrative around verifiable contributions. Research activity, trial participation, manufacturing, partnerships and employment can all be relevant when accurately described. Explain what is taking place in Europe and what remains elsewhere in the group. If a development program is uncertain, make that uncertainty clear. Avoid treating an early result as a promise of clinical benefit for all patients or implying that a planned investment is already operational. Scientific credibility depends on how limits are communicated as much as on positive findings.

Audience separation is essential. US habits of direct-to-consumer prescription-drug advertising should not simply be exported. French law tightly restricts public medicine advertising, with prescription status and reimbursement among the relevant conditions and specific exceptions governed by the text. ^[3] Corporate communication, disease awareness, scientific exchange and product promotion require their own assessment. A website available from France does not become exempt because its campaign was conceived at American headquarters.

Develop relationships through appropriate expertise and transparency. Medical and scientific teams should guide scientific exchanges; patient engagement needs a clear purpose and suitable safeguards; executive communication can explain strategy and investment. Disclose partnerships as required and avoid presenting stakeholder participation as endorsement. Media material should distinguish company interpretation from independently established findings. When discussing a study, make its design, population and stage intelligible enough for a reader to understand what can and cannot be concluded.

For a US biotech entering Europe, credibility can be built before a commercial launch through the quality of its evidence and its understanding of local systems. Measure progress in terms relevant to the stage of development, such as informed scientific dialogue, readiness for access discussions and confidence among prospective employees or partners. The reputation objective is a dependable account of the company's work. That account must remain accurate as research, authorization and access decisions evolve.